Concordia International (TSX: CXR), the Healthcare company, has received a rating update from a Wall Street analyst on September 11. Bloom Burton’s analyst David Martin, PhD, MBA reiterates their Hold rating on the shares.
Read also: Here’s Why Arrowhead (ARWR) Skyrocketed Over 50% Today
Concordia International has an analyst consensus of Hold.
Concordia International’s market cap is currently C$4.14M and has a P/E ratio of 0. The company has a Price to Book ratio of -0.
Concordia International Corp. is a pharmaceutical company, which engages in owning and licensing a diversified portfolio of branded and generic prescription products. It operates through the Concordia North America and Concordia International segments.
The company’s shares closed on Friday at C$24.20, close to its 52-week low of C$19.02.
